### efp\*ta




Innovative Medicines Initiative: Ebola+ programme

Magda Chlebus Director Science Policy Paris, 10 March 2015

European Federation of Pharmaceutical Industries and Associations



#### **European Union's mobilisation**





#### **Ebola: the challenges**

- \* Evolving epidemic
- \* No treatment/vaccines and no rapid diagnostics for use in the field
- \* Rapid scaling up of candidate vaccine doses needed is difficult;
- \* Current vaccine candidates require very cold temperatures for stability during transport;
- \* Deployment (reaching those most in need) is challenging;
- \* Adherence to vaccination regimens is challenging;
- \* Range of products needed for current and future outbreaks.



#### Industry response: beyond competition

- \* Engage with national health agencies
- ★ Engage with national and international research funding organisations to accelerate R&D of products that can impact on the current epidemics
- \* Join forces across companies
  - \* Screening all companies portfolios to identify suitable antiviral candidates
  - \* Innovative Medicines Initiative
- \* Global coordination




# EU Research funding mechanisms: 17 Ebola projects

- \* When?
  - \* As soon as WHO rang the alarm bell
- \* What?
  - \* Vaccines, Therapeutics, Diagnostics
  - \* Basic research, Preparedness, Social sciences
- \* How?
  - \* Horizon 2020
  - \* Innovative Medicines Initiative
  - \* Framework Programme 7



## Innovative Medicines Initiative – Europe's partnership for health





#### **Ebola+ programme overview**

From Idea to Project start = 2-4 months!!

IMI2 Ebola and other filoviral haemorrhagic fevers programme Joint Information repository, Scientific Advisory Board, Ethics Board

Development

Manufacturing

Deployment

Diagnostics

**Pipelines** 

Topic 1: Vaccine development Phase I, II, III

Topic 2: Manufacturing

Topic 3: Stability during transport and storage

Topic 4: Deployment & compliance with vaccination regimens

Topic 5: Rapid diagnostic tests

VSV-EBOVAC Sclavo Vacc. Assoc. EBOMAN Vibalogics, Janssen EBODAC LSHTM, Janssen

EbolaMoDRAD
Public Health Institute
Sweden

**FILODIAG** 

EBOVAC 1 LSHTM, Janssen

GNA Biosolutions

EBOVAC 2 Inserm, Janssen

Mofina
Public Health England,
Altona



Total budget: € 215 million

#### Why the Innovative Medicines Initiative?

### Collaboration between stakeholders and disciplines is a MUST to address the threat

Vaccinologists, infectious disease specialists, anthropologists, novel technologies, diagnostics, private industry

A neutral trusted platform facilitates exchange and helps align stakeholder's interests



#### A concerted international effort





















### And many more...



#### **Summary**

- \* Massive, flexible and fast industry response
- \* International coordination and collaboration: avoiding overlaps, align with WHO steer
- **\*** Joining forces:
  - \* Across companies and sectors
  - \* Across public and private sectors
  - \* Across borders
- \* Continued effort current and future epidemics



